RxDoctor Payments Data

Narothama Reddy Aeddula, MD

Nephrology · Evansville, INNPI 1255581641

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $88,851 of the $125,249 with a category attached, or 70.9%. 14 manufacturers reported payments, led by Travere Therapeutics, Inc. at 47.4% of the total. Among nephrology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$125,249in general payments, 2019–2025

Across 243 payments — averaging $515.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$59K
  • Calliditas Therapeutics US Inc.$53K
  • AstraZeneca$11K
  • Amgen$365
  • Bayer$181
  • AbbVie$145
  • plus $557 from 8 others

What the payments were for

  • Consulting fees$6,0005%
  • Speaking & faculty fees$88,85171%
  • Travel & lodging$24,32019%
  • Food & beverage$6,0415%
  • Education$380%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$125,249 in reported general payments places this provider in the 95th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$374,879
Medicare patients
985
Services billed
4,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol159$153,038
JardianceEmpagliflozin107$90,319
JanuviaSitagliptin Phosphate37$35,278
LokelmaSodium Zirconium Cyclosilicate19$9,041
DapagliflozinDapagliflozin Propanediol16$7,755
Sevelamer Carbonate20$4,462
Cinacalcet Hcl50$4,133
Potassium Chloride79$4,071
Spironolactone200$2,080
Amlodipine Besylate286$1,776
Tamsulosin Hcl153$1,717
Fenofibrate31$1,567
Losartan Potassium206$1,478
Furosemide258$1,359
Calcitriol83$1,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$11,278$162,080178 claims
Boehringer IngelheimJardiance$107$90,319107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 238 nephrology providers in Indiana.

Other nephrology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →